A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.
about
VortioxetineProfile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literatureA brief history of the development of antidepressant drugs: from monoamines to glutamatePrevention of Relapse and Recurrence in Adults with Major Depressive Disorder: Systematic Review and Meta-Analyses of Controlled TrialsPharmacology and clinical potential of vortioxetine in the treatment of major depressive disorder.A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agUnder the Influence: The Interplay among Industry, Publishing, and Drug Regulation.The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.Vortioxetine: a New Treatment for Major Depressive Disorder.Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats.New advances in the treatment of generalized anxiety disorder: the multimodal antidepressant vortioxetine.Vortioxetine (brintellix): a new serotonergic antidepressantDepression and cerebrovascular disease: could vortioxetine represent a valid treatment option?Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorderWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015.A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD.An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder.Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders.A review of antidepressant therapy in primary care: current practices and future directions.Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological TreatmentsNew generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder.Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorderSerotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunctionVortioxetine for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?Vortioxetine for the treatment of depression.Pharmacokinetic evaluation of vortioxetine for the treatment of major depressive disorder.Vortioxetine: a review of its use in major depressive disorder.Vortioxetine for the treatment of major depressive disorder.A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.A randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder.Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder.Vortioxetine for depression in adults.A Population Pharmacokinetic-Pharmacodynamic Meta-Analysis of Vortioxetine in Patients with Major Depressive Disorder.Suicidal Risks in Reports of Long-Term Controlled Trials of Antidepressants for Major Depressive Disorder II.The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone.Effects of sertraline, duloxetine, vortioxetine, and idazoxan in the rat affective bias test.The impact of antidepressant treatments on family functioning in adults with major depressive disorder: a post hoc comparison of vortioxetine and agomelatine.Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.The efficacy and safety of 5 mg/d Vortioxetine compared to placebo for major depressive disorder: A meta-analysis.
P2860
Q26773284-AEF25953-83DA-4A50-986C-9D52C78F19E2Q26796436-89B3A104-5B3B-4B55-A853-5A33E4177644Q27028050-81CDA895-B908-4736-9610-F7C391BFCFA1Q28088645-878E46EB-3155-4947-AF5B-6E1213BA0A88Q33933912-1C6D1157-E4A1-4A8D-9D08-9138AF8B2A30Q34041642-C0FCFC12-5065-4890-AD3E-63B346321FCFQ34046215-E5F46DBD-2A3F-44DF-BF74-35C9A2EC63DFQ34497909-A668931D-0307-4C3D-8873-BA0F73561BA9Q34505568-A4BDB7DA-C21C-4B07-B7C6-23706B2C2257Q34559591-24E8260E-E2F5-4BBA-A110-C1351FF45D6DQ34676776-3BB11DE3-7C7A-4BB2-8CE9-D6A5DB45B169Q34976273-82D07715-598C-4E5C-B63F-8037ED26C435Q35426685-83365A52-4EB9-4CCE-B2A0-641BD4870CC3Q35536869-FD81652A-82B6-4340-8F39-548B65FF0175Q35560309-6C7F4DE0-8160-4EE4-AE01-1A98FB725CDDQ35607556-EDB2866D-6C87-42CE-82CC-41A3C81A8BEDQ35746646-F8630001-6C44-46B3-B2AC-70D69C246521Q35862776-EBD45E8E-DB41-48C6-9C57-868FCCA20FE8Q37070398-1CE8E731-58A6-4500-8B0D-011FA49DFC0AQ37197216-A601ADC0-7A3F-4B3B-8C86-394420C9D89EQ37601281-3E70AE5D-C7A1-47B5-A5F2-9D9377464E28Q37692558-988E60F8-8590-429D-A133-712A750DAB93Q38125568-0BC5550E-FA23-4EFA-B7B6-6EEDAD7EE3A8Q38156001-7D2B6983-7C62-400F-B13D-1C07F511D88AQ38199987-65ED6F15-4345-4355-A6DB-98FB706A77F5Q38200656-CD29525D-5253-4D4A-9D21-2501CF27BAACQ38242001-70EFF482-DB65-4821-8A6A-6982AB9D5110Q38244159-55B53F35-D621-40B9-9DF3-BCF305B77181Q38249999-D9824053-8B25-46C4-935D-281964922B91Q38271646-C5AB1ED6-8187-44CB-B539-B90FBCE176B3Q38371388-CDA16048-4CCA-4340-ADCF-44AC71822CB2Q38506798-DDE0A9CC-594F-4115-A463-D1CE37F5F7F8Q38693309-27A5CA79-13D7-48FA-A569-2F4E77C89357Q40366493-D21DBBDD-F94B-400A-AFB0-ED2C833E433CQ42290223-F003B2C8-280D-4BA5-BD02-32F5761D710EQ47141387-CE1363FE-B17F-44AC-9363-1AEE6D09663DQ47397404-6A46764F-7E68-47D9-838E-1192C6649B85Q47950300-48B6E56C-4D1B-4E1C-B9FA-554988D13B3EQ48038510-2E3C7004-DCC2-4E5C-B2AD-1E8C2AB59540Q48285675-3191EEE1-6E16-4D6D-A782-4DD0E19FD5AE
P2860
A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
A randomized clinical study of ...... ith major depressive disorder.
@ast
A randomized clinical study of ...... ith major depressive disorder.
@en
A randomized clinical study of ...... ith major depressive disorder.
@nl
type
label
A randomized clinical study of ...... ith major depressive disorder.
@ast
A randomized clinical study of ...... ith major depressive disorder.
@en
A randomized clinical study of ...... ith major depressive disorder.
@nl
prefLabel
A randomized clinical study of ...... ith major depressive disorder.
@ast
A randomized clinical study of ...... ith major depressive disorder.
@en
A randomized clinical study of ...... ith major depressive disorder.
@nl
P2093
P2860
P356
P1476
A randomized clinical study of ...... ith major depressive disorder.
@en
P2093
Henrik Loft
Ioana Florea
Jean-Philippe Boulenger
P2860
P304
P356
10.1177/0269881112441866
P407
P577
2012-04-09T00:00:00Z